1133748-69-2

Upstream product

• 1133748-67-0 (R)-tert-butyl 3-methyl-4-(1-phenylpyrido[3,4-d]pyridazin-4-yl)piperazine-1-carboxylate 

Downstream Products

• 1133749-25-3 (R)-(3-methyl-4-(1-phenylpyrido[3,4-d]pyridazin-4-yl)piperazin-1-yl)(morpholino)methanone 
• 1133748-65-8 (R)-(4,4-difluorocyclohexyl)(3-methyl-4-(1-phenylpyrido[3,4-d]pyridazin-4-yl)piperazin-1-yl)methanone 
• 1133749-05-9 (R)-(3-methyl-4-(1-phenylpyrido[4,3-d]pyridazin-4-yl)piperazin-1-yl)(tetrahydro-2H-pyran-4-yl)methanone 
• 1133749-36-6 (R)-(4,4-difluoropiperidin-1-yl)(3-methyl-4-(1-phenylpyrido[3,4-d]pyridazin-4-yl)piperazin-1-yl)methanone 
• 1133748-84-1 4-((2R)-2-methyl-4-(phenylcarbonyl)-1-piperazinyl)-1-phenylpyrido[3,4-d]pyridazine 

Relevant academic research and scientific papers

Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines

Pyridopyridazine antagonists of the hedgehog signaling pathway are described. Designed to optimize our previously described phthalazine smoothened antagonists, a representative compound eliminates a PXR liability while retaining potency and in vitro metab

ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING

The present invention relates generally to compounds represented in Formula (I), pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.